The opioid epidemic — responsible for 80,000+ deaths annually in the United States — has driven a fundamental rethinking of perioperative and chronic pain management. The transition from opioid-centric to multimodal analgesia (MMA) — combining multiple agents with different mechanisms to achieve adequate analgesia at lower doses of each — represents the most significant shift in pain management practice of the past decade. Enhanced Recovery After Surgery (ERAS) protocols, now implemented across major surgeries at leading U.S. health systems, embed MMA as a core element alongside early mobilization, normothermia maintenance, and fluid optimization. Our OR and surgery catalog and patient care section support ERAS program supply requirements.
The MMA Framework: Mechanisms and Agents
Multimodal analgesia combines agents acting at different pain pathway levels: (1) Peripheral sensitization reduction — NSAIDs (ibuprofen, ketorolac, celecoxib) and COX-2 inhibitors block prostaglandin synthesis at injury sites, reducing peripheral sensitization and inflammation; gabapentinoids (gabapentin, pregabalin) reduce central sensitization by blocking α2δ calcium channels; ketamine (sub-anesthetic doses 0.1–0.5 mg/kg) blocks NMDA receptors involved in central sensitization and "wind-up." (2) Pain signal transmission — local anesthetics (bupivacaine, ropivacaine, liposomal bupivacaine — Exparel) block sodium channels in peripheral nerves, producing opioid-free analgesia lasting hours to days with local or regional block application; acetaminophen blocks a CNS endocannabinoid mechanism producing central analgesia without peripheral anti-inflammation. (3) Descending modulation — SNRIs (duloxetine) and TCAs enhance descending noradrenergic pain inhibition, particularly relevant for chronic pain management. Combining agents from these categories reduces opioid consumption by 30–50% compared to opioid monotherapy while maintaining equivalent or superior analgesia scores in ERAS RCTs.
Regional Anesthesia: The Opioid-Free Surgical Option
Ultrasound-guided nerve blocks — now the standard of care for total joint arthroplasty, shoulder surgery, and thoracic procedures — provide anatomically targeted opioid-free analgesia of 12–24 hours (single-shot) or 48–72 hours (continuous catheter). Total knee arthroplasty nerve blocks (adductor canal block + IPACK block) allow same-day physical therapy and discharge within 24–48 hours in ERAS programs vs 3–4 day stays with opioid-based protocols. Liposomal bupivacaine infiltration at surgical sites provides 72-hour controlled release of local anesthetic. Regional anesthesia supplies including ultrasound-guided nerve block needles, nerve block catheters, infusion pumps, and local anesthetic are available through our OR and surgery section.
